文献速递主动脉外科

再次手术对主动脉弓重建手术的影响:来自多中心国家注册研究的数据

The influence of reoperation on aortic arch reconstructive surgery: Evidence from a multicenter, national registry.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-03-20

该研究基于多中心国家注册数据,分析2002至2021年因主动脉弓修复在循环停止下手术的2481例患者,其中374例(15%)为再次手术。再次手术组住院死亡率为12%,原发组与再次手术组在住院死亡率和复合终点上无显著差异,但再次手术组输血需求和ICU/住院时间更高。老年、急性主动脉夹层和体外循环时间延长是再次弓部手术死亡和并发症的独立预测因素。

要点

  • 再次主动脉弓手术住院死亡率为12%,原发与再次手术组死亡率无显著差异。
  • 再次半弓置换组住院死亡率显著高于原发半弓组,但全弓置换组间无差异。
  • 老年、急性主动脉夹层和体外循环时间延长是再次弓部手术不良结局的独立预测因素。

核心结论

  • 经过选择的主动脉弓再次手术可以接受的安全性实施。
  • 老年、急性主动脉夹层和体外循环时间延长与再次弓部手术更差的住院结局相关。

研究设计与样本

  • 多中心国家注册研究,收集2002至2021年在循环停止下接受主动脉弓修复(半弓或全弓置换,伴或不伴象鼻/冷冻象鼻)的患者数据,包括急性主动脉夹层。
  • 既往有心脏开放手术史的患者定义为再次手术病例(主动脉再次手术组和其他再次手术组),共2481例患者,其中374例(15%)为再次手术队列。

主要发现

  • 再次主动脉弓手术总体住院死亡率为12%。
  • 原发、主动脉再次手术和其他再次手术组的住院死亡率分别为9.3%、11%和14%,差异无统计学意义(P = .132)。
  • 原发、主动脉再次手术和其他再次手术组的MMOM发生率分别为30%、34%和39%,差异无统计学意义(P = .075)。
  • 两个再次手术组的输血需求和ICU/住院时间均更高(P < .001)。
  • 再次半弓置换组住院死亡率显著高于原发半弓组(P = .014),而原发与再次全弓置换组间死亡率和MMOM无显著差异(P > .05)。

关键数值与推荐

  • MMOM复合终点定义为住院死亡、卒中、透析依赖的肾衰竭、深部胸骨伤口感染、再手术和延长通气>40小时。
  • 多变量分析确定老年、急性主动脉夹层和体外循环时间(对数转换)延长是再次弓部手术住院死亡和MMOM的独立预测因素。

临床怎么用

  • 对于有既往心脏手术史的患者,再次主动脉弓手术可在经过选择的情况下安全实施,但需关注输血需求和ICU/住院时间增加。
  • 老年、急性主动脉夹层和体外循环时间延长的再次弓部手术患者风险更高,应优化手术技术和围术期管理。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the in-hospital outcomes of patients undergoing reoperative aortic arch repair and identify risk factors for mortality and morbidity using data from a multicenter, national registry. METHODS: We collected data on patients undergoing aortic arch repair (hemiarch or total arch replacement with or without elephant trunk/frozen elephant trunk) under circulatory arrest between 2002 and 2021, including those with acute aortic dissection. Patients with a history of previous open-heart surgery were defined as the redo cases (aortic-redo group and other-redo group). The primary outcomes were operative mortality and a modified Society of Thoracic Surgeons composite end point for mortality and major morbidity (MMOM). The MMOM composite end point was defined as operative mortality, stroke, dialysis-dependent renal failure, deep sternal wound infection, reoperation, and prolonged ventilation >40 hours. Blood transfusion rates were also analyzed. RESULTS: Overall, 374 (15%) of 2481 patients were in the redo cohort. The overall operative mortality of aortic arch reoperations was 12%. Although redo patients had a significantly higher comorbidity burden, no significant difference was identified for the operative mortality among primary, aortic-redo, and other-redo groups (9.3% vs 11% vs 14%; P = .132), and for the MMOM incidence (30% vs 34% vs 39%; P = .075). Additionally, transfusion requirements and intensive care unit/hospital stays were higher in both redo groups (P < .001). To further analyze the redo group, all patients were divided into 4 groups: Primary hemiarch group (n = 1800), primary total-arch group (n = 307), redo hemiarch group (n = 266), and redo total-arch group (n = 108). Operative mortality was significantly higher in the redo hemiarch group (P = .014). In contrast, there was no significant difference in mortality or MMOM between primary and redo total-arch groups (P > .05). Multivariable analyses identified older age, acute aortic dissection, and prolonged cardiopulmonary bypass time (log-transformed) as independent predictors of both operative mortality and MMOM in reoperative arch repair. CONCLUSIONS: This study of a national registry demonstrated that selected aortic arch reoperations can be performed with acceptable safety. Older age, acute aortic dissection, and prolonged cardiopulmonary bypass time are associated with worse operative outcomes. Further studies are needed to optimize surgical techniques and perioperative care, in addition to selecting patients who would benefit most from reoperative open arch surgery.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Qin C, Stevens LM, Atoui R, et al. The influence of reoperation on aortic arch reconstructive surgery: Evidence from a multicenter, national registry. J Thorac Cardiovasc Surg. 2026. PMID: 41865785. doi:10.1016/j.jtcvs.2026.03.572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。